One of the nation’s top academic medical centers, the University of Rochester Medical Center forms the centerpiece of the University’s health research, teaching, patient care and community outreach missions. Over the last five years, the UR School of Medicine and Dentistry has received almost $1.3 billion in total research funding.
The University of Rochester Medical Center has established a Center for Human Experimental Therapeutics (CHET) to advance knowledge and improve health through groundbreaking research. The CHET vision is to enable anyone, anywhere to receive care, participate in research, and benefit from its advances.
Biogen, Inc. is a multinational biotechnology company specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative and autoimmune diseases to patients worldwide. Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company’s portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BioMarin.com.
Greater Rochester Health Foundation (Health Foundation) was created in 2006 when the not-for-profit MVP Health Plan acquired the not-for-profit HMO Preferred Care. The value of Preferred Care was returned to the community through MVP’s purchase price of $232 million to create a foundation dedicated to improving the health of the Greater Rochester community, Between 2007 and 2013, Greater Rochester Health Foundation has distributed $53 million to hundreds of organizations in the nine-county service area that are working to improve the health of their communities in our strategic areas of focus, health care delivery, neighborhood health status improvement; and prevention.
The Burroughs Wellcome Fund, founded in 1955, is dedicated to advancing the biomedical science by supporting research and education. The Fund primarily supports early career scientists in underfunded areas of biomedical research and science education in North Carolina.
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases.
Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups.
Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases.
Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.
University of Rochester Clinical and Translational Science Institute (CTSI) was one of the first 12 institutions to be funded by the Clinical and Translational Science Award Program at the National Institutes of Health. Since its inception in 2006, the CTSI has been continually funded by the CTSA program, which is now administered by the National Center for Advancing Translational Sciences. In its first ten years, the CTSI provided pilot funding and training that helped researchers and students secure approximately $58 million in additional external funding to advance their studies.